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The  costs  of  cancer  care  grow  exponentially.  It has  been  argued  that there  is  a  linear relation  between
costs  and  outcome:  the  more  a country  spends  on  cancer  care,  the  better  the  outcome.  We  try  to  dispel
this  myth,  by  showing  that the  relation  is not  linear  at all and  by describing  other  factors  in the  cancer
care  delivery  process  that  have  an  impact  on outcome.
We show  that  there  is  a correlation  between  health  care  expenditure  and  life expectancy  at birth,  but
that  there  is no  correlation  between  number  of deaths  per  100,000  and  cost  per person  spent  on cancer  in
general,  neither  in  lung,  breast,  colorectal  and  prostate  cancer.  Furthermore,  a  decrease  in survival  can  be
related  to accessibility,  affordability  or  equity  issues,  but also  to factors  such  as life  style.  In  the real  world
the  process  of  cancer  delivery  is  complex  and  dynamic,  with  many  (potential)  innovations.  When  efﬁcacy
is  proven  and  an innovation  is  considered  clinically  relevant,  the  innovation  has  to  be incorporated  in
evidence  based  clinical  guidelines.  However,  implementation  in  such  a guideline  is still  no  guarantee  forlinical  relevance
uidelines
optimal  adoption  and  diffusion  of  an  innovation.
Cancer  care  delivery  also  goes  beyond  matters  related  to health-systems  and  cancer  costs,  new  tech-
nologies,  reimbursement  agencies,  hospitals,  and  health-care  professionals  by  increasingly  involving
shared  decision  making.  An  optimal  process  of cancer  care  delivery  consists  of the  use  of new and  exist-
ing  diagnostic  tests  and  treatment  strategies  of  high  quality  and  is effective,  safe,  patient  centred,  efﬁcient
and  timely.  Such  health  system  is highly  recommended  and  all  stakeholders  in  society  will  beneﬁt.© 2014  The  Authors.  Published  by  Elsevier  Ltd.  
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There is a widely held belief in public policy circles that higher
spending results in better outcomes for cancer patients [1,2]. Yet
the evidence for this is complex and many associations do not
hold up on further scrutiny [3]. Health expenditures differ world-
wide and generally there is a correlation between higher spending
on health-care per se and composite outcome measures of health
such as life expectancy. In developed countries total expenditures
on health care have continued to increase substantially. Between
1995 and 2010 this rise in the USA was  from 13.6% to 17.6% of its
Gross Domestic Product (GDP) (Table 1) [4]. In Europe the trend is
license.
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Table  1
Health expenditures as % of GDP and per capita and life expectancy at birth in USA and European Union, 1995 and 2010 (cost in D).
Health expenditure, total (% of GDP) Health expenditures per capita Life expectancy at birth
1995 2010 1995 2010 1995 2010
United States 13.6 17·61 2743 6026 75·62 78·54
European  Union:
Austria  9.58 10·98 2105 3634 76·72 80·38
Belgium  7.61 10·49 1564 3329 76·84 80·23
Bulgaria  5.23 7.58 60 351 71.05 73.51
Croatia  6.85 7.81 237 769 72.08 76.48
Czech  Republic 6.69 7.46 274 1027 73.07 77.42
Denmark  8.13 11.12 2070 4577 75.21 79.1
Estonia  6.32 6.35 121 657 67.54 75.43
Finland  7.85 8.96 1471 2895 76.41 79.87
France 10.36 11.67 2007 3381 77.75 81.37
Germany  10.11 11.51 2287 3407 76.42 79.99
Greece  8.67 10.79 779 2103 77.59 80.39
Iceland  8.43 9.28 1620 2685 77.98 81.9
Ireland  6.57 9.19 906 3105 75.57 80.9
Italy  7.22 9.55 1052 2377 78.01 81.74
Latvia  5.78 6.66 84 558 66.39 73.48
Lithuania  5.37 7.05 73 572 69.01 73.27
Luxembourg  5.57 7.85 2061 5998 76.51 80.63
Malta  5.63 8.49 433 1249 77.14 80.95
Netherlands  8.33 12.11 1652 4160 77.4 80.7
Norway  9.14 9.34 2285 5884 77.74 81
Poland  5.48 6.98 146 623 71.89 76.2
Portugal  7.52 10.73 640 1688 75.31 79.03
Romania  3.22 5.95 39 335 69.46 73.46
Slovak  Republic 6.06 9.01 162 1058 72.25 75.11
Slovenia  7.46 8.97 575 1511 73.96 79.42
Spain  7.44 9.6 826 2120 77.98 81.63
Sweden  7.96 9.56 1676 3447 78.74 81.45
Switzerland  9.33 10.89 3126 5636 78.42 82.25
United  Kingdom 6.75 9.6 997 2558 76.84 80.4
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ource: Data Worldbank [4], exchange rate: 1$≈0.732D
imilar, albeit less marked, indicative of important differences in
he level and in the rate of growth of health care expenditures
etween USA and Europe. In the USA on average D6026 is spent
er capita compared to the European average of D2441. The lat-
er topped by Luxembourg and Norway with D5998 and D5884 per
apita, respectively, compared to D335 and D351, respectively, for
omania and Bulgaria (Table 1).
As health-care expenditure has been increasing, so has life
xpectancy. In the USA the life expectancy at birth has increased
rom 75.6 years in 1995 to 78.5 years in 2010 (Table 1). In the
7 member states of the European Union (EU) the average life
xpectancy at birth improved from 75.8 years in 1995 to 79.6 years
n 2010. The difference between EU countries with the highest and
owest life expectancies is around 8 years for women and 12 years
or men  [6]. Factors inﬂuencing this gain were rising living stan-
ards, improved lifestyle, better education and improved access to
ealth services [6]. Fig. 1 shows the correlation between the health
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Fig. 1. Relation life expectancy at birth and health expenditure (%GDP).
ource:  Data Worldbank [4], Data derived from Table 1.1205 2441 75.8 79.63
care expenditure and life expectancy (Pearson correlation: 0.52,
p = 0.0032).
But what is the situation for cancer? Cancer is the second leading
cause of mortality in most developed countries after cardiovascular
diseases. In 2008, 2.45 million people were diagnosed with cancer
in the EU. While changes in lifestyle and advances in prevention,
early detection, and treatment have considerably reduced cancer
incidence and mortality, 1.23 million people still died in the EU of
this disease [3]. Death rates for all types of cancer in males and
females have modestly declined since 1995, although the decline
has been less than for cardiovascular diseases [6]. The economic
burden of cancer is high. In the EU in 2009 the total costs were D126
billion, D51.0 billion of which related to EU health-care systems.
Taken by EU country, the economic cost varied from D16 per person
in Bulgaria to D184 per person in Luxembourg [3]. But is there a
direct causal relationship between expenditure on cancer care and
outcomes?
It has been argued that there is a linear relation between costs
and outcomes in cancer care: higher spending results in better out-
comes [1,7]. Philipson et al. report that the USA spends more on
cancer care per capita than any European country, but this is paral-
leled by greater survival gains. The adjusted average survival from
diagnosis was 11.1 year for cancer patients diagnosed in the US
from 1995–1999, compared with 9.3 years among the European
countries [1]. The authors suggest the value of these additional
survival gains has exceeded the additional costs of care. However,
there are several reasons why  survival is not a good indicator to
compare countries.De  Vries et al. already described that a decrease in survival apart
from deterioration of care or of access to it, can also be attributed
to improved diagnosis of premalignant lesions, to deleterious
changes in the distribution of prognostic factors and changes in the
24 C.A. Uyl-de Groot et al. / Journal of Cancer Policy 2 (2014) 22–29
Table 2
Death rates per 100.000 and health care costs of all cancers and of lung, breast, colorectal and prostate cancer in European countries in 2009, by country.a
Death rates per 100,000 [5] Adjusted cost per person (D) [3]
All
cancers
Lung
cancer
Breast
cancer
Colorectal
cancer
Prostate
cancer
All
cancers
Lung
cancer
Breast
cancer
Colorectal
cancer
Prostate
cancer
Austria 206.30 37.8 28.8 22.3 33.3 119 11 16 13 12
Belgium  216.40 52.3 34.2 24.2 29.3 71 6 9 9 8
Czech  Republic 253.10 47.9 25.5 35.9 35.0 104 9 13 13 11
Denmark  243.20 58.4 35.5 31.9 47.9 69 6 8 8 8
Estonia  237.40 40.4 26.1 28.2 55.7 82 7 13 11 7
Finland  176.90 32.2 23.5 17.9 34.8 127 10 16 13 14
France  211.90 42.5 28.8 22.9 31.6 97 6 13 9 13
Germany  207.00 40.5 29.5 24.8 30.7 171 15 27 20 20
Greece  203.30 47.2 27.1 17.6 26.8 128 11 20 10 16
Ireland  242.50 50.6 34.9 27.7 41.7 88 8 9 10 7
Italy  210.60 42.4 28.2 23.1 24.0 96 8 9 11 8
Luxembourg  215.20 46.9 31.4 27.3 37.5 141 16 20 17 14
Netherlands  239.30 57.0 32.9 28.5 39.1 123 12 18 16 8
Poland  251.8 58.7 24.2 28.9 33.4 78 11 9 9 5
Portugal  201.30 28.5 24.3 29.8 36.9 61 4 8 6 7
Slovak  Republic 246.10 41.4 26.2 37.8 33.9 103 9 14 11 10
Slovenia  258.20 45. 33.2 35.8 52.6 90 7 10 9 10
Spain  197.80 40.8 21.6 27.3 26.5 96 5 12 10 11
Sweden  192.80 31.4 23.1 23.3 51.1 92 7 10 6 11
United  Kingdom 228.50 51.3 31.2 23.1 37.1 92 8 10 10 7
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a Selection of countries based on available data.
istribution of socio demographic characteristics in a population
8]. Furthermore, differences in survival may  be inﬂuenced by dif-
erences in adherence to a healthy life style after cancer diagnosis
s healthy lifestyle is increasingly considered to improve out-
omes [9]. Moreover the number of patients with a second primary
umour is increasing [10,11]. So there is a shift in the composi-
ion of the patient population. Since treatment of second and later
rimary tumours, due to limitations related to successful previ-
us treatments (chemotherapy maximum dose already achieved;
rug-resistance issues), can be hindered this may  negatively affect
verall survival ﬁgures of these tumours.
In order to have a better comparison between cost and out-
ome, we studied the relation between cancer mortality and costs
n EU countries (Table 2). Fig. 2 shows that there is almost no cor-
elation between number of deaths per 100,000 and cost spent on
ancer per person (Pearson correlation: −0.31, p = 0.1836)), imply-
ng that countries reporting low number of deaths per 100,000 did
ot spend more money per person.
Considering this relation for lung, breast, colorectal and prostate
ancer the results were even more pronounced. For lung cancer the
orrelation was positive, implying that on average less money spent
n lung cancer did not result in worse outcome (Pearson correla-
ion: 0.19, p = 0.4258)) (Fig. 3.1). For breast, colorectal and prostate
ancer there also was no linear relation, the correlations were −0.03
0
50
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0 50 100 150 200
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100,000
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EU countries
Fig. 2. Relation cancer mortality versus costs in EU countries (2009).
ource: OECD statistics [5], Fuengo-Fernandez [3], *Selection of countries based on
vailable data, Data derived from Table 2.(p = 0.8915), −0.07 (p = 0.7688) and −0.30 (p = 0.1913), respectively
(Figs. 3.2–3.4).
With respect to costs of cancer care new cancer medicines
dominate the public debate [12]. However, although costs of
drugs are a signiﬁcant factor accounting for around 27% of total
costs, hospital inpatient care is responsible for over 56% of direct
cancer care costs, a factor that is often overlooked [3]. Moreover
a disproportional amount of the money is spent during the last 30
days of life, particularly involving inpatient care. In the USA  the
costs of the latter period were almost 30% of total cancer care costs
and even in the EU this was  as high as 20% [13,14]. Therefore it is
important to discuss drug expenditure in cancer as part of a much
wider issue, that encompasses the structural, organisational and
cultural aspects of cancer care.
The beneﬁts of novel expensive anticancer drugs with respect to
survival are increasing. While major impacts have been observed
with some agents in a limited number of tumour types, this was
mainly in the non-curative, advanced setting where most of those
and other targeted agents were studied. Assuming a higher like-
lihood of beneﬁt and success, the next generation of molecularly
targeted medicines as well as immunotherapies are increasingly
tested in the adjuvant and neo-adjuvant settings.
Given these developments clinicians as well as lay press empha-
sise the need for more balanced pricing of cancer drugs. In economic
terms, price must reﬂect value and/or society’s willingness to pay, a
subjective position that harnesses many public, political and ﬁscal
factors [15]. However, the last two  decades prices of newly intro-
duced cancer drugs have increased more than twentyfold, from an
average of D300–500 per patient per month (carboplatin) in the
early nineties to more than D10,000 per patient per month (ipili-
mumab). In 2012, 12 cancer drugs were approved by the FDA, 11 of
which were priced above D73,000 per treatment per patient [16].
In  this respect a uniform system of expressing costs per value is
missing. Cost-effectiveness analysis is widely used to support deci-
sion making for which costs per QALY is frequently used. When
prices are based on real value, it could be expected that the cost
per QALY would largely remain the same. Those treatments with
the best balanced cost per QALY gained would then be reimbursed.
The UK National Institute for Health and Care Excellence (NICE)
for instance, states that for drugs the cost per QALY should not
C.A. Uyl-de Groot et al. / Journal of Cancer Policy 2 (2014) 22–29 25
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innovation, i.e. administration of bortezomib in relapsed/refractory
multiple myeloma (registered in 2004 for 2nd and 3rd line therapy
based on a phase II trial [21]; phase III data became available in
0
5
10
15
20
25
30
Proporon
of mulple
myeloma
paents
Average
proporon
Netherlands
Minimum
Maximumig. 3. (1) Mortality versus costs in EU countries: lung cancer (2009), (2) Mortality ve
olorectal cancer (2009), (4) Mortality versus costs in EU countries: prostate cancer
ource: OECD statistics [5], Fuengo-Fernandez [3], *Selection of countries based on 
ormally exceed D36,180 (1£≈“D1.206”. However using the cost
er QALY as a principle denominator is not accepted by everyone,
ince not all relevant factors, such as conﬂicting outcomes, severity
f disease, rarity of disease, the limited availability of other treat-
ent options and budget impact, are taken into account in this
arameter. Moreover cancer medicines are often used for different
ancers and/or within one cancer at different stages of disease (e.g.
rastuzumab), with different cost per QALY outcomes. To address
his technology assessment programmes are increasingly looking
o use of multi-criteria decision analysis (MCDA) as an approach to
rioritise expensive medicines. However, practical applications in
ancer care are still rather limited.
Beyond costs there are clearly wider issues that affect outcome.
here is no easy direct, linear relationship between spending and
utcomes, such as mortality, survival or progression free survival,
n cancer care (e.g. see Figs. 2 and 3). In the real world the process
f cancer care delivery is complex and depends on several other
actors like the health-care system, the adoption and diffusion of
he innovations in a system, quality of the clinical guidelines, the
economic) behaviour of several stakeholders and characteristics
f patients. These other factors are however much more difﬁcult
o tackle then, for example the cost of cancer medicines and are
ften neglected. We  need to aim for health-care delivery systems
n which cancer care is of highest possible quality, effective, safe,
ersonalised, timely, efﬁcient and equitable [17]. But how is this to
e achieved?
doption and diffusion of innovations in cancer care
When  an innovation, e.g. a new diagnostic test and/or treat-
ent opportunity, is developed the diffusion of the innovation
epends on several factors. Diffusion shows how an innovation
preads among (potential) users. According to Rogers, diffusion of
n innovation is a ﬁve-step process percolating through a series of
ommunication channels over a period of time among the membersosts in EU countries: breast cancer (2009), (3) Mortality versus costs in EU countries:
).
ble data, Data derived from Table 2.
of  a similar social system [18]. Factors of importance that deter-
mine diffusion are knowledge, awareness, persuasion and interest.
Cancer care is rich in evidence-based innovations. However, the
adoption of these innovations is quite heterogeneous and differs
between countries and even between regions within countries. The
way a new innovation is perceived, the characteristics of the indi-
viduals who  may  adopt the change and contextual and managerial
factors within the care delivery determine to a great extent the
rate of diffusion [19]. In this respect important stakeholders are
the reimbursement agencies, health insurers, hospitals, doctors and
patients. However, when an innovation is reimbursed by a reim-
bursement agency, access to the innovation could still be different
between hospitals or regions within one country [20]. The adop-
tion of an innovation often follows an S shape, when plotted over
time. Fig. 4 shows that within one health system the diffusion of an2003 2004 2005 2006 2007 2008 2009 2010
Year
Fig. 4. Uptake of bortezomib in the Netherlands, period 2004–2010.
Source: Blommestein [20].
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005) [22], indeed followed an S shape, but the rate of adoption
iffered remarkably between the regions [20].
It is well known that doctors who have participated in clinical
rials are more eager to adopt an innovation than colleagues who
id not. The ‘trial’ doctors and ‘trial’ centres already have experience
ith the innovation, thus when there is a proven clinical beneﬁt
hey are inclined to administer the innovation to their patients.
hese are the so called early adopters. In this respect the role of key
linical leaders is very important as they have most inﬂuence during
he adoption process. Key opinion leaders also have more contacts
ith developers of innovations, have greater exposure to the mass
edia and are involved in the development of clinical guidelines.
hilst rapid diffusion of new innovations has been championed by
 number of parties, mostly those constituents focused on medical
echnologies, the drive to bring ‘innovations’ to clinical practise is
ot necessarily a win-win situation [19]. Key opinion leaders can be
oo enthusiastic about an innovation. Sometimes there is too much
ocus on the gain in progression free survival, rather than in overall
urvival, side-effects or even cost. For example in 2011 the Food
nd Drug Administration (FDA) decided to revoke an approval of
008 for the breast cancer drug bevacizumab. The FDA concluded
hat “based on new information the considerable risks of taking
evacizumab cannot be justiﬁed when there is no proof of a beneﬁt
n breast cancer patients” [23]. While the drug is still available for
ther types of cancer treatment, the approval for use in breast can-
er was retracted. Furthermore whilst innovation covers all forms
f technology and practice the reality is that apart from cancer
edicines and associated diagnostics there has not been a similar
rive in other areas, such as mental health innovations in cancer
24], or even in the major modality of cancer control, surgery, to
eliver in these areas.
vidence  based clinical guidelines
Even where cost effective pathways and/or technological inno-
ations have been demonstrated the subsequent diffusion into
ealth-care systems is dependent on clinical take up. This demands
nclusion in cancer clinical guidelines. However, there are reserva-
ions about the content and reliability of oncology clinical practice
uidelines [25]. Many recent published guidelines did not meet the
riteria in the checklist and many existing guidelines are outdated.
eames et al. concluded that there is much room for improvement
o make guidelines as methodologically sound and evidence based
s possible [25]. In addition these guidelines are not very easy to
se in daily practice. Moreover especially in case of drug trials
here are in general restricting eligibility criteria, which means that
atients with signiﬁcant co-morbidity or another primary tumour
n the past are often excluded from participation. Guidelines do
ot frequently take into account the limitations of clinical trials
n reﬂecting the real world. This is one of the reasons why futile
reatment may  occur. In this respect it is of interest that in 2012
he American Society Clinical Oncology (ASCO) recommended in
heir “Choosing Wisely items” [26] to eliminate treatment that is
nlikely to be effective in patients who meet all of the following cri-
eria: Patients with low performance status (3 or 4); who have not
eneﬁted from prior standard therapy; who have no further stan-
ard treatment options for their disease; and who are not eligible
or a clinical trial. For these patients, emphasis should be placed
n palliative and supportive care, that can lead to evidence-based
ncrease quality of life and, in some cases, increase survival [27].
Cancer  care is a very dynamic process; the number of potential
nnovations is high. For example at the moment there are over 900
ew molecular entities in (drug-)development as well as vast num-
ers of new approaches in screening, radiotherapy, pathology and
urgery. The cancer research space is complex and very dynamic.
eveloping and keeping up to date cancer care guidelines is a labourancer Policy 2 (2014) 22–29
intensive  and time-consuming process that needs input from many
stakeholders, since delivering cancer care is typically multidisci-
plinary. Ensuring health-care systems follow appropriate cancer
clinical guidelines is an essential step in delivering better outcomes.
However, this ﬁrst requires appropriate and timely guidelines to be
constructed.
Clinical relevance versus statistical signiﬁcant outcome
A  registered drug is not necessarily a relevant drug and a statis-
tical signiﬁcant difference is not the same as a clinical meaningful
beneﬁt. At the moment, several organisations, such as ASCO, NICE,
European Society of Medical Oncology and the Dutch Committee on
Expensive Cancer Drugs, are dealing with this question. Depending
on several factors such as cancer type, line of therapy and subsets of
patient groups different criteria are formulated according to clini-
cal measurable outcomes, like response, progression free survival,
overall survival, adverse events and quality of life. In this respect,
especially treatments used in the curative setting (primary end-
point: overall survival) and treatments used in the non-curative
setting (any other endpoint) should be assessed differently.
There is of course a risk-beneﬁt trade off between improvement
in (overall) survival on one hand and toxicity and quality of life
issues on the other, that should be taken into account. Ellis et al.
already drafted ASCO recommendations in order to stimulate clini-
cal trials with new drugs or regimens based on molecular or biologic
markers which will have the potential to signiﬁcantly improve the
lives of patients (in terms of survival and quality of life) and lead
to real advances in therapy [27]. The result will be “smaller and
smarter” and more efﬁcient trials [27,28]. Improvements of at least
5–20% in overall survival are seen as clinical meaningful outcomes
[27,29].
As previously discussed, the adoption of an innovation is not
necessarily implemented when it is ﬁrst reported in a clinical guide-
line. However, there are also other factors why  doctors did not use
the innovation. Sometimes they are not aware and need informa-
tion (feedback) about the treatments and outcomes of treatments
they have given to patients and compare these with other col-
leagues and/or hospitals. This information must be evaluated and
used to deﬁne a plan to improve their functioning. As such medical
professional organisations are performing audits and increasingly
clinical, process and outcome data are collected. Patient registries
are useful tools [30,31]. Key elements are collecting data, sharing
data and communication between doctors [32]. Although adop-
tion is rather an individual process, it is advisable to give the
feedback on a hospital or department level rather than on an indi-
vidual level [32]. In this respect, ASCO’s Quality Oncology Practice
Initiative (QOPI®) programme is also of interest [33]. This initia-
tive is an oncologist-led, practice-based quality assessment and
improvement programme. The goal is to promote excellence in can-
cer care by helping practices create a culture of self-examination
and improvement. The process employed for improving cancer
care includes measurement, feedback and improvement tools for
haematology–oncology practices [33].
Cancer care delivery also goes beyond matters related to health-
systems and cancer costs, new technologies, reimbursement
agencies, hospitals, and health-care professionals. The position of
patients is also becoming central to the debate on what sort of can-
cer care systems society expects. Whilst public policy may  rest on
macro economics in cancer care the reality is that in many coun-
tries the popular view of what is expected for patients shapes much
of the strategic discourse. However, to implement shared deci-
sion making (SDM) in daily practice there is a need to signiﬁcantly
change the philosophy, culture and roles of patients and doctors’
[17].
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D
cFig. 5. Process oiscussion
We  here challenge the linear relation between costs and out-
ome in cancer care. Such an assertion is one of the central mythser care delivery.of  cancer today. The fact this is not the case calls for more insightful
and broad learning from best practices across health-care systems.
This is of major importance as the costs of cancer care delivery
are increasing in an unsustainable manner. Increasing health care
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xpending will result in limited and unequal access, particularly
ith regard to new innovations with high acquisition costs, such
s new oncology drugs, radiotherapeutic advances, laboratory tests
tc. Policy makers have to make reimbursement decisions consid-
ring both rapid and equal accessibility to promising technologies
s well as decisions about how to divide available resources among
iseases.
It has been noted that new cancer drugs often reach USA patients
arlier than European patients [1]. To solve the problem of delay
n access and frequently limited available evidence the ‘coverage
ith evidence development’ policy (or “conditional approval”) is an
ption: new drugs are reimbursed under the condition that addi-
ional research will be conducted [30,31]. However, we describe
hat there are also other factors involved in the cancer care delivery
rocess suggesting that limitations in availability of new tech-
ologies may  be beneﬁcial if there is limited knowledge of the
echnologies clinical impact and cost effectiveness. Fast does not
lways mean a better deal for patients or society, despite the pre-
ailing public policy which is for ever quicker approval.
There are many clinical practice guidelines in cancer care and
hese are known to have a substantial effect on practice pat-
erns and patient outcomes [25]. However, they have substantial
eﬁciencies. Furthermore, due to changes in the population, the
ynamic and complex process of cancer care, including the rapid
rowth of new innovations, the applicability of the guidelines in
aily practice is rather difﬁcult and also limited. This is pointed out
n Fig. 5, which presents the dynamic process of delivering cancer
are.
One reason is that, due to an ageing population, there will be
ore elderly patients with cancer, involving more patients with co-
orbidity. In these situations, doctors have to balance between a
onger life for patients and the side effects of treatment, but without
aving much evidence available for this patient group. There is an
ncreasing need for optimal treatment of cancer patients with a
ariety of ‘concomitant’ chronic conditions [34]. As the evidence is
ostly not found in clinical trials, it should be collected from daily
ractice, e.g. by patterns of care studies.
SDM between doctors and patients is currently receiving much
ttention. It is assumed that the involvement of patient preferences
avours less extensive treatment. Therefore, SDM has also been pro-
oted as a strategy to reduce overtreatment and costs [35,36].
owever, SDM could also lead to higher and sometimes unreal-
stic demands, leading to overtreatment. Recently it was already
ndicated that the increasing expectations about the role of SDM
n clinical and health policy in general and in cancer in particular
hould not be overestimated [37,38].
In the end, appropriate use of innovations and accessibility
epend on various factors, such as regulatory and health-
are system, organisational characteristics, (dynamic) process of
nnovations, and socio-cultural characteristics of numerous stake-
olders (including patients). An evaluation and comparison of
ealth policies around cancer across Europe will provide more
nsight in this dynamic and complex process. Furthermore, it will
ive valuable information that can enhance evidence-based deci-
ion making for both health care providers and policy makers. Such
n evaluation could improve appropriate use of new and exist-
ng diagnostic tests, treatment strategies and pathways in order
o reach a cancer care delivery system of optimal quality, effec-
ive, safe, person centred and timely. When this system is also
fﬁcient and equitable all stakeholders in the society will beneﬁt
rom it.onﬂict of interest
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